Drug intelligence / Profile preview

HHTP

Development stage: Preclinical
Lead developer: Haihe
Modality: Small Molecules

Overview

HHTP is a small molecule drug candidate currently in the preclinical stage of development by Haihe Biopharma (also known as Chengdu Haihe Medical Technology). It is being investigated for the treatment of solid tumors. As of the current reporting, specific details regarding its biological target or mechanism of action have not been publicly disclosed, reflecting its early-stage status within the company's oncology pipeline. The compound is part of a broader research effort by Haihe Biopharma to develop novel therapeutics for malignant tumors.

Targets

EZH1EZH2 (Histone-lysine N-methyltransferase EZH2)

Beyond the preview

Go deeper on HHTP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HHTP.

Explore the full profile